GlassScriptPhysician profile
Freud Telemaque
NPI 1902395973
$1,693.33
in general payments reported to CMS, 2019-2025
16 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.79 · 2021: $98.54 · 2022: $302 · 2023: $594 · 2024: $382 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.16 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $473.24 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $202.16 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $196.61 | 2022-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $114.82 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $108.56 | 2024-2025 | Repatha, Otezla, Repatha |
| Gilead Sciences, INC. | $105.67 | 2025 | |
| Abbvie INC. | $84.57 | 2021-2023 | Mavyret |
| Glaxosmithkline, LLC. | $83.79 | 2019 | |
| Abbott Laboratories | $60.83 | 2022 | |
| Lucid Diagnostics INC. | $51.52 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $43.22 | 2023 | Quviviq |
| Ucb, INC. | $42.88 | 2021 | |
| Medtronic, INC. | $41.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.88 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $22.73 | 2023 | Cologuard Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.47 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freud Telemaque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.